Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-27. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
==== A. The nasal soft tissues ==== Nasal skin – Like the underlying bone-and-cartilage (osseo-cartilaginous) support framework of the nose, the external skin is divided into vertical thirds (anatomic sections); from the glabella (the space between the eyebrows), to the bridge, to the tip, for corrective plastic surgery, the nasal skin is anatomically considered, as the: Upper third section – the skin of the upper nose is thin, subcutaneous fat layer is thicker and relatively distensible (flexible and mobile), but then tapers, adhering tightly to the osseo-cartilaginous framework, and becomes the thinner skin of the dorsal section, the bridge of the nose. Middle third section – the skin overlying the bridge of the nose (mid-dorsal section) is the thinnest, least distensible, nasal skin, because it most adheres to the support framework. Lower third section – the skin of the lower nose and tip is significantly thicker and less mobile due to a higher density of sebaceous glands. This increased thickness can often efface the underlying cartilaginous framework, requiring more aggressive surgical definition in the tip area. The subcutaneous fat layer is very thin. Nasal lining – At the vestibule, the human nose is lined with a mucous membrane of squamous epithelium, which tissue then transitions to become columnar respiratory epithelium, a pseudo-stratified, ciliated (lash-like) tissue with abundant seromucous glands, which maintains the nasal moisture and protects the respiratory tract from bacteriologic infection and foreign objects.
The three substrates of this enzyme are crotonic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are butyric acid and oxidised NAD+. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is butanoate:NAD+ Delta2-oxidoreductase. This enzyme is also called enoate reductase. This enzyme participates in phenylalanine metabolism. It has cofactors: flavin adenine dinucleotide and iron–sulfur protein.
In July 1977, the Ogaden War started after Barre's government used national liberation to justify the incorporation of the predominantly Somali Ogaden of Ethiopia into a Greater Somalia. Ogaden had rich agricultural lands, infrastructure, and strategically important areas. In the first week, Somali forces took southern and central Ogaden. For most of the war, the Somali army scored continuous victories over the Ethiopian army, pursuing till Sidamo. By September 1977, Somalia controlled 90% of the Ogaden and captured strategic cities such as Jijiga and pressured Dire Dawa, threatening the train route from the city to Djibouti. After the siege of Harar, a massive, unprecedented Soviet intervention of 20,000 Cuban forces and several thousand Soviet experts came to aid Ethiopia's communist Derg. By 1978, the Somali troops were ultimately pushed out of the Ogaden. This shift in support by the Soviets motivated the Barre government to seek allies elsewhere. It eventually settled on the Soviets' Cold War rival, the United States, which had been courting the Somali government for some time. Somalia's initial friendship with the Soviet Union and later partnership with the United States enabled it to build the largest army in Africa. A new constitution was promulgated in 1979, under which elections for a People's Assembly were held. In October 1980, the SRSP was disbanded, and the Supreme Revolutionary Council was reestablished. The regime was weakened further in the 1980s as the Cold War drew to a close and Somalia's strategic importance was diminished.
A group of South American species formerly placed in the genus Datura are now placed in the distinct genus Brugmansia (Brugmansia differs from Datura in that it is woody (the species being shrubs or small trees) and has indehiscent fruits.) The solanaceous tribe Datureae, to which Datura and Brugmansia belong, has recently acquired a new, monotypic genus Trompettia J. Dupin, featuring the species Trompettia cardenasiana, which had hitherto been misclassified as belonging to the genus Iochroma. Datura specialists Ulrike Preissel and Hans-Georg Preissel accept only nine species of Datura, but Kew's Plants of the World Online lists the following 14 (out of which its related The Plant List does not include D. arenicola, D. lanosa and D. pruinosa as accepted spp.):
Sources: en.wikipedia.org
A feature exploited in the expansion of the genetic code is the fact that the aminoacyl tRNA synthetase often does not recognize the anticodon, but another part of the tRNA, meaning that if the anticodon were to be mutated the encoding of that amino acid would change to a new codon. In the ribosome, the information in mRNA is translated into a specific amino acid when the mRNA codon matches with the complementary anticodon of a tRNA, and the attached amino acid is added onto a growing polypeptide chain. When it is released from the ribosome, the polypeptide chain folds into a functioning protein. In order to incorporate a novel amino acid into the genetic code several changes are required. First, for successful translation of a novel amino acid, the codon to which the novel amino acid is assigned cannot already code for one of the 20 natural amino acids. Usually a nonsense codon (stop codon) or a four-base codon are used. Second, a novel pair of tRNA and aminoacyl tRNA synthetase are required, these are called the orthogonal set. The orthogonal set must not crosstalk with the endogenous tRNA and synthetase sets, while still being functionally compatible with the ribosome and other components of the translation apparatus. The active site of the synthetase is modified to accept only the novel amino acid. Most often, a library of mutant synthetases is screened for one which charges the tRNA with the desired amino acid. The synthetase is also modified to recognize only the orthogonal tRNA. The tRNA synthetase pair is often engineered in other bacteria or eukaryotic cells.
assuming a Gaussian surface high distribution with curve fits presented by Arcoumanis et al. and Jedynak among others. It has been repeatedly observed that engineering surfaces do not demonstrate Gaussian surface height distributions e.g. Peklenik. Leighton et al. presented fits for crosshatched IC engine cylinder liner surfaces together with a process for determining the
=== 2000 census === As of the census of 2000, there were 40,852 people, 16,108 households, and 10,808 families residing in the city. The population density was 2,571.8/sq mi. There were 17,374 housing units at an average density of 1,093.8 per square mile. The racial makeup of the city was 91.68% White, 0.53% African American, 1.22% Native American, 1.14% Asian, 0.21% Pacific Islander, 2.65% from other races, and 2.56% from two or more races. Hispanic or Latino of any race were 6.09% of the population. There were 16,108 households, out of which 33.3% had children under the age of 18 living with them, 51.1% were married couples living together, 11.7% had a female householder with no husband present, and 32.9% were non-families. 26.1% of all households were made up of individuals, and 10.4% had someone living alone who was 65 years of age or older. The average household size was 2.49 and the average family size was 2.99. In the city, the population was 26.4% under the age of 18, 9.6% from 18 to 24, 29.3% from 25 to 44, 21.9% from 45 to 64, and 12.7% who were 65 years of age or older. The median age was 35 years. For every 100 females, there were 94.5 males. For every 100 females age 18 and over, there were 91.7 males. The median income for a household in the city was $39,409, and the median income for a family was $46,094. Males had a median income of $36,457 versus $24,480 for females. The per capita income for the city was $18,570.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.